Abstract
Background: The HERC family contains six members from HERC1 to HERC6 that are featured with the HECT domains that exerts ubiquitin ligase activity and the RCC1-like domains that are involved in cell cycle regulation. Although identified as early as 1990s, their biological functions are extensively studied in recent years. More and more researches have demonstrated that the HERC ubiquitin ligases are widely engaged in carcinogenesis, however, there lacks a comprehensive and instructive analysis.
Methods: The PubMed database was searched by keywords of individual HERC proteins (such as HERC4) and cancer. The emerging roles of HERC proteins in cancer and the specific mechanisms were collectively analyzed and discussed.
Results: HERC proteins belong to the HECT domain-containing ubiquitin ligases that can identify and mediate the ubiquitination of specific substrate proteins. All HERC ubiquitin ligases except HERC6 have been assigned one or more than one ubiquitination substrates. In all of HERCs, HERC1 and HERC2 have been widely studied, in contrast, there are no reported studies yet on protein ubiquitination mediated by HERC6. Dependent on the protein substrates, HERC proteins may act as a tumor suppressor or oncoprotein in specific cancer types. For example, HERC4 is believed to contribute to carcinogenesis of solid tumors such as lung cancer, but it suppresses the proliferation of myeloma cells.
Conclusion: HERC proteins as ubiquitin ligases are widely involved in various cancers. Targeting at specific HERC proteins could be a strategy for the treatment of certain cancers.
Keywords: HERC proteins, ubiquitin ligase, proteasomal degradation, cancer, tumor suppressor, oncoprotein.
Current Pharmaceutical Design
Title:The Emerging Roles of the HERC Ubiquitin Ligases in Cancer
Volume: 24 Issue: 15
Author(s): Xinliang Mao*, Gautam Sethi, Zubin Zhang and Qi Wang
Affiliation:
- Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405,China
Keywords: HERC proteins, ubiquitin ligase, proteasomal degradation, cancer, tumor suppressor, oncoprotein.
Abstract: Background: The HERC family contains six members from HERC1 to HERC6 that are featured with the HECT domains that exerts ubiquitin ligase activity and the RCC1-like domains that are involved in cell cycle regulation. Although identified as early as 1990s, their biological functions are extensively studied in recent years. More and more researches have demonstrated that the HERC ubiquitin ligases are widely engaged in carcinogenesis, however, there lacks a comprehensive and instructive analysis.
Methods: The PubMed database was searched by keywords of individual HERC proteins (such as HERC4) and cancer. The emerging roles of HERC proteins in cancer and the specific mechanisms were collectively analyzed and discussed.
Results: HERC proteins belong to the HECT domain-containing ubiquitin ligases that can identify and mediate the ubiquitination of specific substrate proteins. All HERC ubiquitin ligases except HERC6 have been assigned one or more than one ubiquitination substrates. In all of HERCs, HERC1 and HERC2 have been widely studied, in contrast, there are no reported studies yet on protein ubiquitination mediated by HERC6. Dependent on the protein substrates, HERC proteins may act as a tumor suppressor or oncoprotein in specific cancer types. For example, HERC4 is believed to contribute to carcinogenesis of solid tumors such as lung cancer, but it suppresses the proliferation of myeloma cells.
Conclusion: HERC proteins as ubiquitin ligases are widely involved in various cancers. Targeting at specific HERC proteins could be a strategy for the treatment of certain cancers.
Export Options
About this article
Cite this article as:
Mao Xinliang *, Sethi Gautam , Zhang Zubin and Wang Qi , The Emerging Roles of the HERC Ubiquitin Ligases in Cancer, Current Pharmaceutical Design 2018; 24 (15) . https://dx.doi.org/10.2174/1381612824666180528081024
DOI https://dx.doi.org/10.2174/1381612824666180528081024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Surface Plasmon Resonance Imaging (SPRI) Sensor for Cystatin Determination Based on Immobilized Papain
Protein & Peptide Letters Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine
Anti-Cancer Agents in Medicinal Chemistry Myc - What We have Learned from Flies
Current Drug Targets Cytotoxicity of gold(III) Complexes on A549 Human Lung Carcinoma Epithelial Cell Line
Medicinal Chemistry Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response
Current Pharmacogenomics Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry The Neurotensinergic System: A Target for Cancer Treatment
Current Medicinal Chemistry Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Characterization and in vitro Cytotoxicity Evaluation of Meloxicam Loaded PEGylated Mixed Micelles Fabricated Using Quality by Design Approach
Drug Delivery Letters New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer’s Disease
Recent Patents on Anti-Cancer Drug Discovery Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry